

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2021/0310008 A1 Parker et al.

(43) **Pub. Date:**

Oct. 7, 2021

(54) PARN AS A BIOMARKER AND THERAPEUTIC TARGET

(71) Applicant: The Regents of the University of Colorado, a body corporate, Denver,

CO (US)

Inventors: Roy R. Parker, Boulder, CO (US); Shukla Siddharth, Boulder, CO (US)

(21) Appl. No.: 17/266,502

PCT Filed: Aug. 7, 2019

(86) PCT No.: PCT/US19/45540

§ 371 (c)(1),

(2) Date: Feb. 5, 2021

Related U.S. Application Data

Provisional application No. 62/715,688, filed on Aug.

Publication Classification

(51) Int. Cl. C12N 15/113 (2006.01)C12Q 1/6886 (2006.01)

A61K 31/704 (2006.01)A61K 31/7125 (2006.01)A61P 35/00 (2006.01)


(52)U.S. Cl.

CPC C12N 15/1137 (2013.01); C12Q 1/6886 (2013.01); A61K 31/704 (2013.01); A61K 31/7125 (2013.01); C12Q 2600/158 (2013.01); C12N 2310/11 (2013.01); C12N 2320/31 (2013.01); C12N 2310/315 (2013.01); A61P 35/00 (2018.01)

ABSTRACT (57)

Increased PARN as an indicator of a cancer involving loss or reduction in p53 function. PARN is also provided as a therapeutic target for treating a cancer involving loss or reduction in p53 function. Methods of treating a subject having a cancer involving loss or reduction in p53 function based on the level of PARN in a test sample obtained from the subject and administering an effective amount of a PARN inhibitor, alone or in conjunction with another chemotherapeutic agent, to the subject to treat the cancer.

Specification includes a Sequence Listing.



miRNA degradation